G6PD Genotype Mapping Sharpens Hydroxychloroquine Safety Assessment
Hydroxychloroquine sits at the intersection of therapeutic utility and red-cell vulnerability. In patients with G6PD deficiency, the drug can become a hematologic liability if oxidant stress exceeds the erythrocyte’s limited ability to neutralize it. The allele table associated with hydroxychloroquine therapy organizes that risk through a practical genotype framework, pairing common G6PD variants with HGVS nomenclature, protein changes, WHO classification, and dbSNP identifiers. For clinicians, this is more than a catalog of mutations. It is a reminder that a single enzymatic pathway can determine whether an otherwise familiar medication is handled safely or becomes a trigger for hemolysis.
Allele Classes Separate Normal Activity From Deficient Enzyme Function
The table begins with the non-deficient reference state, G6PD B, listed as wild type and assigned a WHO classification of IV/Normal. From there, the variants spread across the usual functional spectrum. Some alleles remain in the normal range despite amino acid substitution, including G6PD A+ with p.Asn126Asp and G6PD Sao Borja with p.Asp113Asn, both classified as IV/Normal. Their presence matters because not every sequence change in G6PD implies clinically relevant enzyme failure. In pharmacogenetics, the critical question is not whether a variant exists, but whether it meaningfully impairs enzymatic reserve under oxidative challenge.
The deficient alleles cluster into the more clinically consequential WHO classes. Several are listed as class III, including G6PD A- haplotypes and variants such as Bangkok, Kalyan-Kerala, and Orissa. Class II alleles, including Mediterranean, Viangchan, Chatham, and the table entry labeled Canton, indicate more severe deficiency. One allele, Villeurbanne, is classified as I/Deficient with CNSHA, a designation that signals chronic non-spherocytic hemolytic anemia and points to a particularly fragile red-cell phenotype. In a patient taking hydroxychloroquine, those distinctions are not academic. They help estimate the probability that oxidative stress will outrun cellular defense.
The Molecular Changes Explain the Hematologic Risk
The table pairs each allele with its nucleotide and protein alteration, allowing the genotype to be read mechanistically rather than as a name alone. G6PD A- is built on the common c.376A>G, p.Asn126Asp change and may include a second pathogenic hit such as c.202G>A, p.Val68Met, or other paired substitutions. In this configuration, the enzyme retains altered structure and reduced stability, leaving red cells less able to maintain NADPH production when challenged. G6PD Mediterranean, with c.563C>T and p.Ser188Phe, has long been recognized as a clinically important deficient allele, and its class II designation reflects the degree of functional compromise clinicians worry about when oxidant drugs are prescribed.
A few entries show why nomenclature discipline matters at the bedside. The table includes GP6D Canton as written, linked to p.Arg459Leu and a deficient WHO class, even though the gene symbol appears inconsistent with the rest of the table. The protein-level consequence remains the relevant point for clinicians: altered enzyme function, reduced protection against oxidative injury, and a greater need for caution with drugs that can stress erythrocytes.
Bedside Implications for Hydroxychloroquine Prescribing
Hydroxychloroquine has a reputation for broad clinical use, but genotype-aware prescribing prevents false reassurance. In a patient with a documented deficient G6PD allele, the practical concern is hemolysis, not abstract genotype labeling. Red cells depend on G6PD to generate NADPH, which sustains reduced glutathione and protects the membrane from oxidative damage. When that defense system is compromised, drug exposure can precipitate anemia, jaundice, dark urine, fatigue, or a rapid fall in hemoglobin, especially if another oxidative stressor is present at the same time.
This allele table supports a more refined approach than a binary “normal” versus “deficient” frame. The severity of deficiency varies across variants, and not all named alleles carry the same functional penalty. Class IV and some class III alleles may not behave identically in every patient, while class II and class I variants imply a more substantial vulnerability. Clinicians reviewing hydroxychloroquine use should therefore interpret a reported G6PD result in the context of the exact allele, not just the gene name.
One sentence matters here: a patient with G6PD deficiency is not simply “screen positive” or “screen negative.”
Why the Classification System Still Matters in Clinical Pharmacogenetics
The WHO categories in the table provide a common language for comparing alleles across populations and laboratories. For hydroxychloroquine, that standardization helps translate molecular data into safer medication decisions. The table also points clinicians toward auxiliary resources such as ClinPGx and the CPIC allele definition table, both of which support genotype interpretation and nomenclature consistency. This is important because G6PD variants are geographically and ethnically distributed, and the same drug can have different implications depending on which allele is present in a given patient.
The updated WHO classifications are not uniformly available for every allele listed, and the table acknowledges that some variants still lack a finalized update. Even so, the overall message remains stable: hydroxychloroquine prescribing should not ignore red-cell enzymology when a patient has a known G6PD variant. The strongest clinical signal comes from the severe end of the spectrum—class II and class I alleles—where the probability of clinically meaningful hemolysis rises as enzymatic reserve falls.
A Genotype Table With Direct Prescribing Consequences
This table is useful because it compresses a large amount of pharmacogenetic information into a format that can be acted on quickly. It identifies common normal and deficient alleles, links them to precise HGVS changes, and anchors each variant to a WHO functional class. For hydroxychloroquine therapy, that structure can inform whether a clinician proceeds with greater vigilance, seeks confirmatory history, or reconsiders the medication in favor of a safer alternative when the red-cell risk looks unacceptable.
The remaining gap is operational rather than conceptual: not every healthcare setting has routine access to genotype-guided prescribing workflows, and not every allele is classified with the same degree of certainty. In practice, the next step is to align the exact G6PD variant with the patient’s medication plan, because the hemolysis risk lives in that pairing, not in the gene name alone.